BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jani D, Allinson J, Berisha F, Cowan KJ, Devanarayan V, Gleason C, Jeromin A, Keller S, Khan MU, Nowatzke B, Rhyne P, Stephen L. Recommendations for Use and Fit-for-Purpose Validation of Biomarker Multiplex Ligand Binding Assays in Drug Development. AAPS J 2016;18:1-14. [PMID: 26377333 DOI: 10.1208/s12248-015-9820-y] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Chen Y, Xue F, Xia G, Zhao Z, Chen C, Li Y, Zhang Y. Transepithelial transport mechanisms of 7,8-dihydroxyflavone, a small molecular TrkB receptor agonist, in human intestinal Caco-2 cells. Food Funct 2019;10:5215-27. [PMID: 31384856 DOI: 10.1039/c9fo01007f] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
2 Elsabahy M, Wooley KL, Hendricksen A, Oh K. Multiplexing techniques for measurement of the immunomodulatory effects of particulate materials: Precautions when testing micro- and nano-particles. Methods 2019;158:81-5. [DOI: 10.1016/j.ymeth.2019.01.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
3 Tu J, Bennett P. Parallelism experiments to evaluate matrix effects, selectivity and sensitivity in ligand-binding assay method development: pros and cons. Bioanalysis 2017;9:1107-22. [DOI: 10.4155/bio-2017-0084] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
4 Schwenk JM, Omenn GS, Sun Z, Campbell DS, Baker MS, Overall CM, Aebersold R, Moritz RL, Deutsch EW. The Human Plasma Proteome Draft of 2017: Building on the Human Plasma PeptideAtlas from Mass Spectrometry and Complementary Assays. J Proteome Res 2017;16:4299-310. [PMID: 28938075 DOI: 10.1021/acs.jproteome.7b00467] [Cited by in Crossref: 104] [Cited by in F6Publishing: 94] [Article Influence: 20.8] [Reference Citation Analysis]
5 Dos Santos MCT, Scheller D, Schulte C, Mesa IR, Colman P, Bujac SR, Bell R, Berteau C, Perez LT, Lachmann I, Berg D, Maetzler W, Nogueira da Costa A. Evaluation of cerebrospinal fluid proteins as potential biomarkers for early stage Parkinson's disease diagnosis. PLoS One 2018;13:e0206536. [PMID: 30383831 DOI: 10.1371/journal.pone.0206536] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
6 Fischer SK, Carrasco-Triguero M, Hong K, Good J, Davancaze T, Nguy T, Li J, Darbonne W, Morimoto A, Zhu Y. Commercial biomarker assays: friend and foe. Bioanalysis 2016;8:2351-62. [PMID: 27704870 DOI: 10.4155/bio-2016-0183] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
7 Verch T, Roselle C, Shank-retzlaff M. Reduction of dilution error in ELISAs using an internal standard. Bioanalysis 2016;8:1451-64. [DOI: 10.4155/bio-2016-0053] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
8 Dos Santos MCT, Barreto-Sanz MA, Correia BRS, Bell R, Widnall C, Perez LT, Berteau C, Schulte C, Scheller D, Berg D, Maetzler W, Galante PAF, Nogueira da Costa A. miRNA-based signatures in cerebrospinal fluid as potential diagnostic tools for early stage Parkinson's disease. Oncotarget 2018;9:17455-65. [PMID: 29707120 DOI: 10.18632/oncotarget.24736] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 10.5] [Reference Citation Analysis]
9 Keller S, Purushothama S. Biomarker assays: is it time for a standalone regulatory guidance? Bioanalysis 2018;10:1893-5. [DOI: 10.4155/bio-2018-0279] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
10 Cowan KJ. Implementing fit-for-purpose biomarker assay approaches: a bioanalytical perspective. Bioanalysis 2016;8:1221-3. [DOI: 10.4155/bio-2016-0070] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
11 Islam R, Kar S, Ritzén H, Hays A, Tayyem R, Barry C, Keyhani A, Zimmer J, Cruz Caturla M, Couerbe P, Warren M, Khadang A, Bourdage J, Lindley K, Williams D, Hughes N, Sheldon C, Satterwhite C, Vija J, Yu M, Boulay I, Stamatopoulos J, Lin J, Cape S, Estdale S, Thomas E, Dinan A, Macneill R, Xiao YQ, Garofolo W, Savoie N, Brown M, Rhyne P, Hristopoulos G, Xu A, Goodwin L, Spriggs F, Xu A, Awaiye K, Hayes R, St Charles J, Bouhajib M, Dimarco C, Dimarco L, Savu SR, Bennett P, Kakkanaiah V, Nehls C, Stouffer B, Tabler E, Briscoe C, Karnik S, Dubey I, Kulagina N, Lindsay J, Beaver C, Williard C, Wang H, Feng H, Malone M, Wells E, Fang X, Moussallie M. Recommendations for classification of commercial LBA kits for biomarkers in drug development from the GCC for bioanalysis. Bioanalysis 2019;11:645-53. [DOI: 10.4155/bio-2019-0072] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
12 Cowan K, Gao X, Parab V, Nguy T, Wu L, Arron JR, Townsend M, Wallin J, Cheu M, Morimoto A, Wakshull E. Fit-for-purpose biomarker immunoassay qualification and validation: three case studies. Bioanalysis 2016;8:2329-40. [PMID: 27712082 DOI: 10.4155/bio-2016-0184] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
13 Elsabahy M, Wooley KL. Reassessment of nanomaterials immunotoxicity. Nano Today 2018;20:10-2. [DOI: 10.1016/j.nantod.2018.01.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
14 O'Bryant SE, Edwards M, Johnson L, Hall J, Villarreal AE, Britton GB, Quiceno M, Cullum CM, Graff-Radford NR. A blood screening test for Alzheimer's disease. Alzheimers Dement (Amst) 2016;3:83-90. [PMID: 27453929 DOI: 10.1016/j.dadm.2016.06.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 4.2] [Reference Citation Analysis]
15 Stephen L. Multiplex Immunoassay Profiling. In: Guest PC, editor. Multiplex Biomarker Techniques. New York: Springer; 2017. pp. 169-76. [DOI: 10.1007/978-1-4939-6730-8_13] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
16 Stephen L, Schwarz E, Guest PC. Multiplex Immunoassay Profiling of Serum in Psychiatric Disorders. Adv Exp Med Biol 2017;974:149-56. [PMID: 28353231 DOI: 10.1007/978-3-319-52479-5_10] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
17 Sperinde G, Hokom M, Peng K, Fischer SK. Bioanalytical challenges in development of ultrasensitive Home Brew assays: a case study using IL-13. Bioanalysis 2019;11:1045-54. [PMID: 31251105 DOI: 10.4155/bio-2019-0012] [Reference Citation Analysis]
18 Zheng X, Xie J, Zhang X, Sun W, Zhao H, Li Y, Wang C. An overview of polymeric nanomicelles in clinical trials and on the market. Chinese Chemical Letters 2021;32:243-57. [DOI: 10.1016/j.cclet.2020.11.029] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 12.0] [Reference Citation Analysis]
19 Neely RJ. Evolution of fit-for-purpose biomarker validations: an LBA perspective. Bioanalysis 2018;10:905-7. [DOI: 10.4155/bio-2017-0267] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
20 Trombetta BA, Carlyle BC, Koenig AM, Shaw LM, Trojanowski JQ, Wolk DA, Locascio JJ, Arnold SE. The technical reliability and biotemporal stability of cerebrospinal fluid biomarkers for profiling multiple pathophysiologies in Alzheimer's disease. PLoS One 2018;13:e0193707. [PMID: 29505610 DOI: 10.1371/journal.pone.0193707] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
21 Moyano HB, Santos RLSR, Pinilla MPR. Validation of an enzyme immunoassay for the quantification of testosterone in green iguana males (Iguana iguana). Gen Comp Endocrinol 2020;287:113343. [PMID: 31809722 DOI: 10.1016/j.ygcen.2019.113343] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
22 Azadeh M, Gorovits B, Kamerud J, MacMannis S, Safavi A, Sailstad J, Sondag P. Calibration Curves in Quantitative Ligand Binding Assays: Recommendations and Best Practices for Preparation, Design, and Editing of Calibration Curves. AAPS J 2017;20:22. [PMID: 29282611 DOI: 10.1208/s12248-017-0159-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
23 Mohd Hanafiah K, Arifin N, Bustami Y, Noordin R, Garcia M, Anderson D. Development of Multiplexed Infectious Disease Lateral Flow Assays: Challenges and Opportunities. Diagnostics (Basel) 2017;7:E51. [PMID: 28880218 DOI: 10.3390/diagnostics7030051] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
24 Elsabahy M, Wooley KL, Hendricksen A, Oh K. Multiple analyte profiling (MAP) index as a powerful diagnostic and therapeutic monitoring tool. Methods 2021;190:26-32. [PMID: 32243921 DOI: 10.1016/j.ymeth.2020.03.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Richards S, Amaravadi L, Pillutla R, Birnboeck H, Torri A, Cowan KJ, Papadimitriou A, Garofolo F, Satterwhite C, Piccoli S, Wu B, Krinos-fiorotti C, Allinson J, Berisha F, Cocea L, Croft S, Fraser S, Galliccia F, Gorovits B, Gupta S, Gupta V, Haidar S, Hottenstein C, Ishii-watabe A, Jani D, Kadavil J, Kamerud J, Kramer D, Litwin V, Lima Santos GM, Nelson R, Ni Y, Pedras-vasconcelos J, Qiu Y, Rhyne P, Safavi A, Saito Y, Savoie N, Scheibner K, Schick E, Siguenza PY, Smeraglia J, Staack RF, Subramanyam M, Sumner G, Thway T, Uhlinger D, Ullmann M, Vitaliti A, Welink J, Whiting CC, Xue L, Zeng R. 2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV): (Part 3 – LBA, biomarkers and immunogenicity). Bioanalysis 2016;8:2475-96. [DOI: 10.4155/bio-2016-4989] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 6.0] [Reference Citation Analysis]
26 Diepeveen L, Roelofs R, Grebenchtchikov N, van Swelm R, Kautz L, Swinkels D. Differentiating iron-loading anemias using a newly developed and analytically validated ELISA for human serum erythroferrone. PLoS One 2021;16:e0254851. [PMID: 34283879 DOI: 10.1371/journal.pone.0254851] [Reference Citation Analysis]
27 Benkerroum N. Retrospective and Prospective Look at Aflatoxin Research and Development from a Practical Standpoint. Int J Environ Res Public Health 2019;16:E3633. [PMID: 31569703 DOI: 10.3390/ijerph16193633] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 6.7] [Reference Citation Analysis]
28 Amaravadi L. Biomarker measurements: how far have we come and where are we heading? Bioanalysis 2016;8:2383-6. [PMID: 27855506 DOI: 10.4155/bio-2016-4987] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
29 Mathews J, Amaravadi L, Eck S, Stevenson L, Wang YC, Devanarayan V, Allinson J, Lundsten K, Gunsior M, Ni YG, Pepin M, Gagnon A, Sheldon C, Trampont PC, Litwin V. Best practices for the development and fit-for-purpose validation of biomarker methods: a conference report. AAPS Open 2022;8. [DOI: 10.1186/s41120-021-00050-1] [Reference Citation Analysis]
30 Dysinger M, Marusov G, Fraser S. Quantitative analysis of four protein biomarkers: An automated microfluidic cartridge-based method and its comparison to colorimetric ELISA. Journal of Immunological Methods 2017;451:1-10. [DOI: 10.1016/j.jim.2017.08.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
31 Hari SK, Gauba A, Shrivastava N, Tripathi RM, Jain SK, Pandey AK. Polymeric micelles and cancer therapy: an ingenious multimodal tumor-targeted drug delivery system. Drug Deliv Transl Res 2022. [PMID: 35727533 DOI: 10.1007/s13346-022-01197-4] [Reference Citation Analysis]
32 Cowan KJ, Geiger A, Hornauer H, Rourick R, Siguenza PY. Performance evaluation of three platforms with ultrasensitive ligand-binding assay potential. Bioanalysis 2017;9:937-46. [DOI: 10.4155/bio-2017-0024] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
33 Metcalfe SS, Kroon FJ, Beale DJ, Miller G. Development of a validation protocol of enzyme immunoassay kits used for the analysis of steroid hormones in fish plasma. Journal of Experimental Marine Biology and Ecology 2018;499:26-34. [DOI: 10.1016/j.jembe.2017.12.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
34 Carlyle BC, Trombetta BA, Arnold SE. Proteomic Approaches for the Discovery of Biofluid Biomarkers of Neurodegenerative Dementias. Proteomes 2018;6:32. [PMID: 30200280 DOI: 10.3390/proteomes6030032] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 7.5] [Reference Citation Analysis]
35 Kunz U, Goodman J, Loevgren U, Piironen T, Elsby K, Robinson P, Pihl S, Versteilen A, Companjen A, Fjording MS, Timmerman P. Addressing the challenges of biomarker calibration standards in ligand-binding assays: a European Bioanalysis Forum perspective. Bioanalysis 2017;9:1493-508. [PMID: 29056059 DOI: 10.4155/bio-2017-0141] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
36 Kontostathi G, Makridakis M, Bitsika V, Tsolakos N, Vlahou A, Zoidakis J. Development and Validation of Multiple Reaction Monitoring (MRM) Assays for Clinical Applications. In: Brun V, Couté Y, editors. Proteomics for Biomarker Discovery. New York: Springer; 2019. pp. 205-23. [DOI: 10.1007/978-1-4939-9164-8_14] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
37 Islam R, Kar S, Islam C, Farmen R. Adaptation of commercial biomarker kits and proposal for ‘drug development kits’ to support bioanalysis: call for action. Bioanalysis 2018;10:945-55. [DOI: 10.4155/bio-2017-0254] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
38 Hogaboom NS, Onishi K, Worobey LA, Boninger ML. Microdialysis to Quantify Inflammatory Cytokines in the Glenohumeral Joint: A Brief Methods Report. Am J Phys Med Rehabil 2019;98:426-9. [PMID: 30461432 DOI: 10.1097/PHM.0000000000001098] [Reference Citation Analysis]
39 Cowan KJ, Amaravadi L, Cameron MJ, Fink D, Jani D, Kamat M, King L, Neely RJ, Ni Y, Rhyne P, Riffon R, Zhu Y. Recommendations for Selection and Characterization of Protein Biomarker Assay Calibrator Material. AAPS J 2017;19:1550-63. [DOI: 10.1208/s12248-017-0146-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
40 Yuill D, Rospo CC, Tadema H, Louber J, Post S. Effectively utilizing the Sponsor Contract Research Organization interaction for successful implementation of critical flow cytometry in the clinic. Bioanalysis 2021;13:1617-25. [PMID: 34601974 DOI: 10.4155/bio-2021-0159] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]